Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 6/20 | 0.89 |
| ▸ | AGTR1 | P30556 | 5/20 | 0.89 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.64 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.64 |
| ▸ | REN | P00797 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29720225 | 0.97 | AGTR2 (0.84) | AGTR2AGTR1NTSR1NTSR2REN | |
| Acetic Acid SCHEMBL34470176 | 0.94 | AGTR2 (0.83) | AGTR2AGTR1NTSR1NTSR2REN | |
| Saralasin SCHEMBL24 | 0.93 | AGTR1 (0.82) | AGTR2AGTR1 | |
| Saralasin SCHEMBL1650804 | 0.92 | AGTR1 (0.80) | AGTR2AGTR1 | |
| SCHEMBL29486803 | 0.90 | AGTR2 (0.76) | AGTR2AGTR1REN | |
| SCHEMBL29599255 | 0.89 | AGTR2 (0.90) | AGTR2AGTR1NTSR1NTSR2REN | |
| SCHEMBL29382642 | 0.88 | AGTR2 (0.78) | AGTR2AGTR1NTSR1NTSR2REN | |
| Angiotensin-Ii SCHEMBL34470359 | 0.88 | AGTR2 (0.90) | AGTR2AGTR1 | |
| Trv-120027 SCHEMBL29382211 | 0.88 | AGTR1 (0.73) | AGTR2AGTR1 | |
| SCHEMBL31332289 | 0.87 | AGTR2 (0.91) | AGTR2AGTR1NTSR1NTSR2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | VICORE PHARMA AB (SE) | 2023-05-25 | — | — | US | disclosed |
| EP-4121165-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | Vicore Pharma AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| US-20220244254-A1 | Screening Methods and Assays for Use with Transmembrane Proteins, in Particular with GPCRs | CONFO THERAPEUTICS N.V. (BE) | 2022-08-04 | — | — | US | disclosed |
| EP-3963329-A1 | SCREENING METHODS AND ASSAYS FOR USE WITH TRANSMEMBRANE PROTEINS, IN PARTICULAR WITH GPCRS | Confo Therapeutics N.V. (BE) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159467-A1 | NOVEL COMPOUNDS USEFUL IN THE TREATMENT AND/OR PREVENTION OF A DISEASE, DISORDER OR CONDITION ASSOCIATED WITH ANGIOTENSIN II | AGTR2, AGTR1, AGT | AGTR2 1/4885AGTR1 2/4885NTSR1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.